BGT-002 (326E) is an orally active dual ACLY inhibitor and PPARalpha agonist. BGT-002 reduces lipogenesis by inhibiting synthesis and promoting efflux. BGT-002 demonstrates efficacy in ameliorating metabolic dysfunction-associated steatohepatitis (MASH) and improving hyperlipidemia in vivo. BGT-002 can be used for hypercholesterolemia and MASH research[1][2][3].
Molecular Weight:
326.47
Purity:
99.35
CAS Number:
[2127387-94-2]
Formula:
C19H34O4
Target:
ATP Citrate Lyase,PPAR
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
